Scynexis, Inc. secures contract for Advance The Development Of Scy-247, A Novel Antifungal Currently In Phase 1 Clinical Trials, For The Treatment Of Invasive Candidiasis And Prophylaxis Of Invasive Fungal Disease As Oral And Ic Formula

United States, Sept. 28 -- United States based Scynexis, Inc. has secured contract from Health And Human Services, Department Of for Advance The Development Of Scy-247, A Novel Antifungal Currently In Phase 1 Clinical Trials, For The Treatment Of Invasive Candidiasis And Prophylaxis Of Invasive Fungal Disease As Oral And Ic Formula . The value of the contract is worth 213943726 USD .

Published by HT Digital Content Services with permission from Pivotal Sources....